Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ITP
MCID: THR001
MIFTS: 53

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 71
Autoimmune Thrombocytopenia 25 58 29 54 71
Immune Thrombocytopenia 12 74 52 25 15
Immune Thrombocytopenic Purpura 25 71
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 25
Autoimmune Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Blood diseases Immune diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1587
NCIt 49 C3991
SNOMED-CT 67 2897005
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 72 C0242584
Orphanet 58 ORPHA71203
UMLS 71 C0242584 C0272286 C0398650
Sources

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Genetics Home Reference : 25 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting. Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding. While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as autoimmune thrombocytopenia, is related to amegakaryocytic thrombocytopenia, congenital and purpura. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of... more...

Sources

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1084)
# Related Disease Score Top Affiliating Genes
1 amegakaryocytic thrombocytopenia, congenital 32.9 THPO MPL ANKRD26
2 purpura 32.1 TNFSF13B THPO MPL ITGB3 ITGA2B GP1BA
3 thrombocytopenic purpura, autoimmune 31.6 THPO MPL ITGB3 ITGA2B ICOSLG GP1BA
4 evans' syndrome 31.2 THPO MPL CD40LG CCR6
5 thrombocytosis 31.1 THPO PF4 MPL
6 acquired thrombocytopenia 31.1 THPO MPL ITGB3 ITGA2B GP1BA
7 mycobacterium tuberculosis 1 31.0 ICOSLG CD8A CD4 CCR6
8 immune deficiency disease 31.0 TNFSF13B ICOSLG CD40LG CD4 CCR6
9 autoimmune disease 31.0 TNFSF13B ICOSLG FCGRT FCGR2B FCGR2A CD40LG
10 endocarditis 30.9 PF4 GP1BA FCGR2A
11 chickenpox 30.8 CD8A CD40LG CD4 CD19 CCR6
12 sarcoidosis 1 30.8 ICOSLG CD8A CD40LG CD4 CCR6
13 thrombocytopenia 3 30.8 THPO MPL
14 lymphadenitis 30.8 ICOSLG CD4 CCR6
15 exanthem 30.8 ICOSLG CD8A CD40LG CD4 CCR6
16 orchitis 30.8 CD8A CD40LG CD4
17 heparin-induced thrombocytopenia 30.7 PF4 FCGR2A CD40LG
18 thyroid gland disease 30.7 ICOSLG CD4 CCR6
19 iga glomerulonephritis 30.7 PF4 CD40LG CCR6
20 myelitis 30.7 ICOSLG CD40LG CCR6
21 splenic sequestration 30.7 THPO MPL CD40LG CD4
22 hemorrhagic disease 30.7 PF4 ITGA2B GP1BA CD40LG
23 aplastic anemia 30.7 THPO MPL ITGB3 ITGA2B CD4
24 igg4-related disease 30.7 TNFSF13B ICOSLG CD4 CCR6
25 infective endocarditis 30.7 PF4 ITGB3 GP1BA FCGR2A
26 autoimmune gastritis 30.6 ICOSLG CD4 CCR6
27 childhood type dermatomyositis 30.6 ICOSLG CD4 CCR6
28 interstitial nephritis 30.6 ICOSLG CD40LG CCR6
29 chronic graft versus host disease 30.6 TNFSF13B CD4
30 coronary thrombosis 30.6 ITGB3 ITGA2B GP1BA
31 qualitative platelet defect 30.6 THPO PF4
32 dysgammaglobulinemia 30.6 ICOSLG CD8A CD40LG
33 acute cystitis 30.5 CD40LG CD4 CCR6
34 kawasaki disease 30.5 FCGR2B FCGR2A CD40LG CD4
35 marginal zone b-cell lymphoma 30.5 CD40LG CD19 CCR6
36 polycythemia vera 30.5 THPO PF4 MPL ITGB3
37 poliomyelitis 30.5 FCGR2A CD8A CD40LG CD4
38 miliary tuberculosis 30.5 CD8A CD40LG CD4
39 spondyloarthropathy 1 30.5 ICOSLG CD40LG CCR6
40 pfeiffer syndrome 30.5 CD8A CD40LG CD4 CD19 CCR6
41 bronchopneumonia 30.5 CD8A CD40LG CD4
42 autoimmune pancreatitis 30.5 TNFSF13B CD40LG CD4
43 pulmonary embolism 30.4 PF4 GP1BA CD40LG
44 monoclonal gammopathy of uncertain significance 30.4 ICOSLG CD40LG CD19 CCR6
45 bacterial infectious disease 30.4 ICOSLG FCGR2A CD8A CD40LG CD4 CCR6
46 central nervous system vasculitis 30.4 CD8A CD40LG CD4 CCR6
47 severe cutaneous adverse reaction 30.4 CD8A CD40LG CD4
48 common cold 30.4 ICOSLG CD4 CCR6
49 anemia, autoimmune hemolytic 30.4 TNFSF13B ICOSLG CD8A CD40LG CD4 CD19
50 dengue disease 30.4 THPO ICOSLG CD8A CD40LG

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization
Sources

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.09 CCR6 CD19 CD4 CD40LG CD8A FCGR2A
2 homeostasis/metabolism MP:0005376 9.8 ANKRD26 CCR6 CD19 CD4 CD40LG FCGR2B
3 immune system MP:0005387 9.44 CCR6 CD19 CD4 CD40LG CD8A FCGR2A
Sources

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Clarithromycin Approved Phase 4 81103-11-9 84029
10
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
11
alemtuzumab Approved, Investigational Phase 4 216503-57-0
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Colchicine Approved Phase 4 64-86-8 2833 6167
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
17
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
18
Caffeic acid Experimental, Investigational Phase 4 501-16-6, 331-39-5 1549111
19
Enoxolone Investigational Phase 4 471-53-4 18526330
20 Calcineurin Inhibitors Phase 4
21 Proton Pump Inhibitors Phase 4
22 Protective Agents Phase 4
23 Antacids Phase 4
24 Anti-Ulcer Agents Phase 4
25 Antiprotozoal Agents Phase 4
26 Antiparasitic Agents Phase 4
27 Antioxidants Phase 4
28 Tubulin Modulators Phase 4
29 Antimitotic Agents Phase 4
30 Antimalarials Phase 4
31 Immunoglobulins, Intravenous Phase 4
32 Rho(D) Immune Globulin Phase 4
33 gamma-Globulins Phase 4
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Cytochrome P-450 CYP3A Inhibitors Phase 4
36 Tin Fluorides Phase 4
37 Pharmaceutical Solutions Phase 4
38 Antineoplastic Agents, Immunological Phase 4
39 Vitamins Phase 4
40 Calcium, Dietary Phase 4
41 Calciferol Phase 4
42 Trace Elements Phase 4
43 Micronutrients Phase 4
44 Vasoconstrictor Agents Phase 4
45 Nutrients Phase 4
46
Calcium Nutraceutical Phase 4 7440-70-2 271
47
leucovorin Approved Phase 3 58-05-9 6006 143
48
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
49
Dapsone Approved, Investigational Phase 3 80-08-0 2955
50
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028

Interventional clinical trials:

(show top 50) (show all 345)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
2 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03540472 Phase 4 tacrolimus
3 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03364764 Phase 4 Sirolimus
4 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
5 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
6 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
7 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
8 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
9 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
10 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
11 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
12 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
13 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
14 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
15 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
16 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
17 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
18 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
19 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
20 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
21 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
22 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
23 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
24 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
25 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
26 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
27 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
28 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
29 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
30 Dexamethasone Compared to Conventional Therapy in the Treatment of Acute Pericarditis: a Superiority Randomized Controlled Trial (Dexa-P) Not yet recruiting NCT04323280 Phase 4 Dexamethasone therapy;Conventional Therapy
31 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
32 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
33 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
34 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Unknown status NCT03164915 Phase 3
35 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
36 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
37 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
38 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
39 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
40 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
41 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
42 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
43 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
44 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
45 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
46 Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP). Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
47 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
48 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
49 An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT01071954 Phase 3
50 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate
Sources

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29
Sources

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

About this section

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

40
Bone, Bone Marrow, T Cells, B Cells, Spleen, Liver, Testes
Sources

Publications for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 3442)
# Title Authors PMID Year
1
Investigation on glucocorticoid receptors within platelets from adult patients with immune thrombocytopenia. 61
31905108 2020
2
The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. 61
32167032 2020
3
Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma. 61
32489885 2020
4
Letter responds to the comment in 'immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'. 61
32470847 2020
5
miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. 61
32428701 2020
6
DNA methylation plays an important role in immune thrombocytopenia. 61
32193101 2020
7
Analysis of the expression profile of long non-coding RNAs MALAT1 and THRIL in children with immune thrombocytopenia. 61
32563217 2020
8
Dexamethasone suppresses the Th17/1 cell polarization in the CD4+ T cells from patients with primary immune thrombocytopenia. 61
32278222 2020
9
IL-10 and IL-17 Expression by CD4+ T Cells is Altered in Corticosteroid Refractory Immune Thrombocytopenia (ITP). 61
32574429 2020
10
Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. 61
32272276 2020
11
Blood Cell Disorders and the Nervous System. 61
32487901 2020
12
Fatigue is common in paediatric immune thrombocytopenia and improves with second-line treatments. 61
32533842 2020
13
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection. 61
32529284 2020
14
[Acquired immune thrombocytopenia: An update on aspects of diagnosis and management relevant for intensive care medicine]. 61
32492744 2020
15
Fatigue in children and adolescents with immune thrombocytopenia. 61
32501532 2020
16
Familial macro thrombocytopenia: role of genetics where morphology fails. 61
32516168 2020
17
Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor. 61
31704777 2020
18
COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature. 61
32497344 2020
19
Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. 61
32374026 2020
20
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report. 61
32500224 2020
21
The never-ending enigma of immune thrombocytopenia. 61
32556133 2020
22
Pregnancy and immune thrombocytopenia: New trends 61
31927816 2020
23
Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia. 61
32523043 2020
24
Large and small platelets-(When) do they differ? 61
32108994 2020
25
Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance. 61
32556153 2020
26
Mechanisms of anti-GPIbα antibody-induced thrombocytopenia in mice. 61
32157300 2020
27
Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes. 61
32162096 2020
28
Reply to: Liu C, et al. Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. 61
32526543 2020
29
Comparative study between chronic immune thrombocytopenia patients and healthy population on Epstein-Barr virus infection status by polymerase chain reaction. 61
32498632 2020
30
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. 61
32129511 2020
31
Correction to A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanoma. 61
32241213 2020
32
Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. 61
32418039 2020
33
A Case of Vancomycin-Induced Immune Thrombocytopenia. 61
32499980 2020
34
Corrigendum to "Subacute sclerosing panencephalitis and immune thrombocytopenia: More than a coincidence?" [Med. Hypotheses 111 (2018) 70-72]. 61
32088521 2020
35
CD70-silenced dendritic cells induce immune tolerance in immune thrombocytopenia patients. 61
32419211 2020
36
Latent and Overt Polyautoimmunity in Children and Adolescents With Immune Thrombocytopenia. 61
32459722 2020
37
Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy. 61
32526595 2020
38
Pulmonary valve replacement after tetralogy of Fallot repair in a patient with immune thrombocytopenia. 61
32445258 2020
39
"ITP" is not always immune thrombocytopenia. 61
32419170 2020
40
Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review. 61
32502698 2020
41
COVID-19 as a cause of immune thrombocytopenia. 61
32445664 2020
42
Immune thrombocytopenia due to COVID-19 during pregnancy. 61
32445584 2020
43
COVID-19-associated immune thrombocytopenia. 61
32420612 2020
44
Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist. 61
31712096 2020
45
Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. 61
32367453 2020
46
Steroid-Induced Diabetes Ketoacidosis in an Immune Thrombocytopenia Patient: A Case Report and Literature Review. 61
32418984 2020
47
Novel compound heterozygous stop-gain mutations of LRBA in a Vietnamese patient with Common Variable Immune Deficiency. 61
32154999 2020
48
CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopenia. 61
32199587 2020
49
Management of Chronic Immune Thrombocytopenia and Presumed Autoimmune Hepatitis in a Child with IKAROS Haploinsufficiency. 61
32319000 2020
50
Retrospective analysis of different regimens for Chinese adults with severe newly diagnosed immune thrombocytopenia. 61
32458092 2020
Sources

Variations for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Sources

Expression for Thrombocytopenia Due to Platelet Alloimmunization

About this section
Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.
Sources

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.97 TNFSF13B ITGB3 ITGA2B ICOSLG FCGR2B FCGR2A
2
ERK Signaling 63
Show member pathways
 13.74 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
3
Akt Signaling 63
Show member pathways
 13.28 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
4
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.19 THPO PF4 MPL ITGB3 ITGA2B ITGA2
5
Phospholipase-C Pathway 63
Show member pathways
 12.97 THPO ITGB3 ITGA2B ITGA2 FCGR2B FCGR2A
6
Allograft rejection 1 36
Show member pathways
 12.77 TNFSF13B ICOSLG CD8A CD40LG CD4
7
NF-kappaB Signaling 4
12.45 TNFSF13B MPL CD8A CD40LG CD19
8
Phagosome 36
12.05 ITGB3 ITGA2 FCGR2B FCGR2A
9
Cell adhesion molecules (CAMs) 36
12.02 ICOSLG CD8A CD40LG CD4
10
ECM-receptor interaction 36
Show member pathways
 12 ITGB3 ITGA2B ITGA2 GP9 GP1BA
11
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
11.96 FCGR2B CD8A CD40LG CD19
12
Reelin Pathway (Cajal-Retzius cells) 63
11.86 ITGB3 ITGA2B ITGA2 CD19
13
Platelet activation 36
11.83 ITGB3 ITGA2B ITGA2 GP9 GP1BA FCGR2A
14
Phagocytosis of Microbes 63
11.73 ITGB3 ITGA2B ITGA2 FCGR2A
15
Innate Lymphoid Cells Differentiation 64
11.7 CD8A CD4 CCR6
16
Dendritic Cells Developmental Lineage Pathway 64
11.65 CD8A CD4 CD19
17
Integrin alphaIIb beta3 signaling 65
Show member pathways
 11.62 THPO MPL ITGB3 ITGA2B GP9 GP1BA
18
Hematopoietic cell lineage 36
11.6 THPO ITGB3 ITGA2B ITGA2 GP9 GP1BA
19
ECM proteoglycans 65
11.52 ITGB3 ITGA2B ITGA2
20
Signaling events mediated by PTP1B 1
11.46 ITGB3 ITGA2B FCGR2A
21
Hematopoietic Stem Cell Differentiation 1
11.43 ITGB3 ITGA2B GP9
22
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.39 THPO MPL ITGB3 ITGA2B ITGA2 GP1BA
23
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.38 ITGB3 ITGA2B ITGA2 GP9
24
Primary immunodeficiency 36
11.2 CD8A CD40LG CD4 CD19
25
G-protein signaling_Rap2B regulation pathway 22
10.88 TNFSF13B THPO PF4 ITGB3 ITGA2B ITGA2
26
Platelet Adhesion to exposed collagen 65
10.75 ITGA2 GP9 GP1BA
27
GP1b-IX-V activation signalling 65
10.61 GP9 GP1BA
Sources

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

About this section

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.31 TNFSF13B MPL ITGB3 ITGA2B ITGA2 ICOSLG
2 integral component of membrane GO:0016021 10.22 TNFSF13B MPL ITGB3 ITGA2B ITGA2 ICOSLG
3 integral component of plasma membrane GO:0005887 9.96 ITGB3 GP9 GP1BA FCGR2B FCGR2A CD8A
4 plasma membrane GO:0005886 9.86 TNFSF13B MPL ITGB3 ITGA2B ITGA2 ICOSLG
5 cell surface GO:0009986 9.76 MPL ITGB3 ITGA2B ITGA2 GP1BA CD40LG
6 integrin complex GO:0008305 9.54 ITGB3 ITGA2B ITGA2
7 external side of plasma membrane GO:0009897 9.32 ITGA2B ITGA2 ICOSLG FCGRT FCGR2B CD8A

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.01 TNFSF13B ICOSLG FCGR2A CD8A CD4 CD19
2 cell adhesion GO:0007155 9.91 ITGB3 ITGA2B ITGA2 GP9 GP1BA CD4
3 blood coagulation GO:0007596 9.81 ITGB3 ITGA2 GP9 GP1BA
4 cell surface receptor signaling pathway GO:0007166 9.77 GP1BA FCGR2B FCGR2A CD8A CD4
5 regulation of megakaryocyte differentiation GO:0045652 9.72 PF4 ITGA2B GP1BA
6 positive regulation of T cell proliferation GO:0042102 9.7 TNFSF13B CD40LG CD4
7 T cell costimulation GO:0031295 9.67 TNFSF13B ICOSLG CD40LG
8 T cell activation GO:0042110 9.65 ICOSLG CD8A CD4
9 integrin-mediated signaling pathway GO:0007229 9.62 ITGB3 ITGA2B ITGA2 CD40LG
10 immunoglobulin mediated immune response GO:0016064 9.58 FCGR2B CD19
11 mesodermal cell differentiation GO:0048333 9.57 ITGB3 ITGA2
12 positive regulation of leukocyte migration GO:0002687 9.56 ITGA2B ITGA2
13 platelet aggregation GO:0070527 9.56 MPL ITGB3 ITGA2B GP1BA
14 immune response GO:0006955 9.56 TNFSF13B PF4 FCGRT FCGR2B CD8A CD40LG
15 platelet activation GO:0030168 9.55 PF4 ITGB3 GP9 GP1BA CD40LG
16 thrombopoietin-mediated signaling pathway GO:0038163 9.46 THPO MPL
17 immunoglobulin secretion GO:0048305 9.4 TNFSF13B CD40LG
18 regulation of immune response GO:0050776 9.17 TNFSF13B ICOSLG FCGR2B FCGR2A CD8A CD40LG

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNFSF13B THPO PF4 CD40LG
2 virus receptor activity GO:0001618 9.43 ITGB3 ITGA2 CD4
3 fibrinogen binding GO:0070051 9.16 ITGB3 ITGA2B
4 coreceptor activity GO:0015026 9.13 ITGB3 CD8A CD4
5 IgG binding GO:0019864 8.8 FCGRT FCGR2B FCGR2A
Sources

Sources for Thrombocytopenia Due to Platelet Alloimmunization

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....